Bell Financial Group trades at $1.23 versus $2.34 fair value, offering 90% upside through platform transformation with $96.8m net cash providing downside protection.
View noteAurizon trades at $3.27 vs fair value $5.39, offering 65% upside through monopoly infrastructure resilience and critical minerals diversification despite coal transition headwinds.
View noteAustralia's largest self-storage operator trading at $1.52 vs $1.45 fair value with 25% market share, 4.1% yield, facing $256m development execution risk
View noteAdrad Holdings: Fair value $0.95 vs current $0.66 (44% upside). HOLD rating. Industrial manufacturer with 4.9% market share, 10.8% EBITDA margins compressing, ROIC 6.4% destroying value. Data centre exposure offset by Asian competition and execution risks.
View noteDevelopment-stage copper producer with fair value A$0.289 vs current A$0.32. Binary Jericho execution risk with 70% combined failure probability creates unfavourable risk-reward for conservative investors.
View noteTemple & Webster fair value $7.76, EBITDA margins expanding 3.1% to 4.5% peak, 70% Amazon expansion risk, 12.8% ROIC, growth-oriented investors
View noteGlobal #1 RV rental operator trading at $2.02 vs $6.55 fair value (224% upside). Tourism recovery from 85% to 100%+ of 2019 levels drives fleet utilisation and margin expansion, though execution risks remain.
View noteSELL rating with fair value $0.40 vs current $0.62. EBITDA margins compressing from 60.9% to 44% as competitive threats emerge.
View noteBUY rating with $2.19 fair value vs $1.94 current price. 24.8% ROIC, debt-free balance sheet, 21-year safety record. Infrastructure supercycle exposure.
View noteSigma Healthcare trades at $3.03 versus $1.33 fair value (56% downside). Strong integration progress but extreme overvaluation at 32.5x EV/EBITDA.
View noteRMA Global trades at $3.50 vs $0.170 fair value assessment. Platform transformation achieving positive cash flow with 35% revenue growth potential through US expansion. Price verification critical.
View noteClinical-stage RNA therapeutics with validated platform technology trading at $1.26 versus $14.41 fair value, offering 1,044% upside potential for growth investors.
View note